Evidence map›Paper›PMID 41552759›Full record

ArticleMolecular therapy. Oncology2026

Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR.

Martin A Boos, Oliver Seifert, Stefanie Sawall, Jessica Genz, Annika Huber, Ilse Hofmann, Roland E Kontermann, Guy Ungerechts, Dirk M Nettelbeck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Martin A BoosClinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Oliver SeifertInstitute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany.
Stefanie SawallClinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Jessica GenzClinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Annika HuberInstitute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany.
Ilse HofmannCore Facility Antibodies, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Roland E KontermannInstitute of Cell Biology and Immunology, University of Stuttgart, 70569 Stuttgart, Germany.
Guy UngerechtsClinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Dirk M NettelbeckClinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study reports a strategy to overcome immune escape of tumors during viro-immunotherapy due to tumor heterogeneity. We pursued a dual-targeting approach of epidermal growth factor receptor (EGFR) and cellular mesenchymal epithelial transition factor (c-MET) facilitated by two bispecific T cell engagers (TCEs) or one trispecific TCE encoded by oncolytic adenoviruses (oAds). Different bi- and trispecific TCE formats were generated and characterized. We showed efficacy of bispecific TCEs single-chain diabody (scDb)-cMET and tandem scFv (taFv)-EFGR

Indexed as

BiTEc-METdual-targetingEGFRimmune evasionMT: Regular Issueoncolytic adenovirussingle-chain diabodysolid tumorstrispecific T cell engagervirotherapy

Identifiers

PMID41552759
PMCPMC12804148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.